Lipocine (NASDAQ:LPCN) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a research note issued on Tuesday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Lipocine Price Performance

Shares of Lipocine stock opened at $3.56 on Tuesday. The stock’s 50-day moving average is $4.51 and its 200 day moving average is $4.62. Lipocine has a one year low of $3.20 and a one year high of $11.79. The firm has a market cap of $19.04 million, a price-to-earnings ratio of -4.68 and a beta of 1.23.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Lipocine stock. Geode Capital Management LLC boosted its holdings in shares of Lipocine Inc. (NASDAQ:LPCN) by 6.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 57,464 shares of the specialty pharmaceutical company’s stock after buying an additional 3,248 shares during the period. Geode Capital Management LLC owned approximately 1.07% of Lipocine worth $280,000 as of its most recent SEC filing. Institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.